AF-CHF trial

GPTKB entity

Statements (61)
Predicate Object
gptkbp:instance_of gptkb:Clinical_Trials
gptkbp:aims_to optimal therapies
gptkbp:aims_to_improve patient quality of life
treatment efficacy
gptkbp:analyzes adverse effects
gptkbp:approves regulatory bodies
gptkbp:concluded_on as of 2023
gptkbp:conducted informed consent
multiple locations
multidisciplinary teams
various demographics
medical researchers
validate hypotheses
assess treatment combinations
gptkbp:contributes_to cardiology research
gptkbp:focuses_on gptkb:atrial_fibrillation
congestive heart failure
https://www.w3.org/2000/01/rdf-schema#label AF-CHF trial
gptkbp:includes randomized control groups
gptkbp:involves longitudinal studies
patients with AF
patients with CHF
gptkbp:is_analyzed_in statistical methods
cost-effectiveness
long-term effects
gptkbp:is_collaborative_with academic institutions
multinational teams
gptkbp:is_compared_to different treatment methods
gptkbp:is_designed_to enhance treatment adherence
reduce hospitalizations
improve survival rates
gptkbp:is_documented_in clinical trial registries
research databases
gptkbp:is_evaluated_by independent reviewers
clinical significance
gptkbp:is_expected_to influence treatment protocols
gptkbp:is_focused_on patient safety
healthcare outcomes
patient-centered outcomes
gptkbp:is_funded_by health organizations
gptkbp:is_monitored_by ethics committees
gptkbp:is_part_of clinical research initiatives
gptkbp:is_related_to gptkb:guidelines
heart failure
cardiovascular health
heart rhythm disorders
gptkbp:is_relevant_to AF management
CHF management
gptkbp:is_supported_by grants
non-profit organizations
pharmaceutical companies
gptkbp:is_utilized_for evidence-based practice
gptkbp:measures patient outcomes
gptkbp:presented_by medical conferences
gptkbp:published_by peer-reviewed journals
gptkbp:reported_by clinical updates
clinical trial sponsors
gptkbp:result medical journals
gptkbp:utilizes placebo controls
gptkbp:bfsParent gptkb:Amiodarone
gptkbp:bfsLayer 7